Insys Therapeutics announced that the Food and Drug Administration (FDA) has approved Syndros (dronabinol oral solution) for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
Syndros is the first FDA-approved dronabinol solution for oral administration, containing the pharmaceutical version of tetrahydrocannabinol (THC). Once opened, Syndros does not require refrigeration for 28 days.
Syndros will be available as a 5mg/mL strength oral solution. The U.S. Drug Enforcement Agency (DEA) has not yet designated a schedule for Syndros. The product is anticipated to launch in the second half of 2016.
For more information call (855) 978-2797 or visit Syndros.com.